NexStar Pharm(NXTR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NexStar Pharm(NXTR)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bill Tomko who wrote (283)	4/1/1998 2:12:00 AM
From: Miljenko Zuanic	Read Replies (1) of 328

Steven: 3 mm from Sumitomo is already in 1Q eps projection. Recent stock activity can be partialy explained by today news on Fujisawa: Restrukturing US and Canada operation, but they keep AmBisome: biz.yahoo.com News from France approval with label expansion in EU union are as important as Japan approval and marketing. Bill: Yes, rumor on SEQU acquisition have no fundamental. Stock is active because they have stady grow in Doxil sale and liposomal cisplatin is moving forward. DEG liposomal formulation show promise for certain drug candidate. mz

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next